levoprotiline | 56433-44-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: levoprotiline
• 英文别名: (-)-oxaprotiline；R-(-)-Oxaprotiline；(+/-)-α-[(methylamino)-methyl]-9,10-ethanoanthracene-9(10H)-ethanol；R-(-)-α-[(methylamino)methyl]-9,10-ethanoanthracene-9(10H)-ethanol；(2R)-1-(methylamino)-3-(1-tetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaenyl)propan-2-ol
• CAS: 56433-44-4
• 化学式: C₂₀H₂₃NO
• 分子量: 293.409
• InChiKey: FDXQKWSTUZCCTM-ZUIJCZDSSA-N

物化性质

• 熔点：
  243-244 °C
• 沸点：
  463.6±30.0 °C(Predicted)
• 密度：
  1.152±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  6.1(b)
• 包装等级：
  III
• 危险类别：
  6.1(b)
• 危险品运输编号：
  UN 3249

反应信息

• 作为产物：
  描述：

  羟丙替林 生成 levoprotiline
  参考文献：
  名称：

  Pharmaceutical use of laevorotatory basic derivative of

  摘要：

  本发明涉及一种新的9,10-乙烯基蒽的左旋衍生物，即R-(-)-α-[(甲基氨基)甲基]-9,10-乙烯基蒽-9(10H)-乙醇，其化学式为I ##STR1## 以及其酸加成盐，涉及含有这些新物质的制药组合物以及用于治疗情感失调、心理植物神经或心理身体障碍的方法。

  公开号：

  US05004755A1

文献信息

• New piperidinylamino-thieno[2,3-D] pyrimidine compounds
  申请人：Dhanoa S. Dale

  公开号：US20050222175A1

  公开（公告）日：2005-10-06

  The invention relates to 5-HT receptor antagonists. Novel piperidinylamino-thieno [2,3-d]pyrimidine compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as pulmonary arterial hypertension, migraine, hypertension, disorders of the gastrointestinal tract, restenosis, asthma, obstructive airway disease, prostatic hyperplasia and priapism, anxiety, depression, schizophrenia, neural injury and stroke. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also provided.

  该发明涉及5-HT受体拮抗剂。公开了由式I表示的新型哌啶基氨基噻吩[2,3-d]嘧啶化合物，以及其合成和用途，用于治疗由5-HT受体直接或间接介导的疾病。这些疾病包括中枢神经系统疾病，如肺动脉高压、偏头痛、高血压、胃肠道疾病、再狭窄、哮喘、阻塞性气道疾病、前列腺增生和勃起功能障碍、焦虑、抑郁症、精神分裂症、神经损伤和中风。还提供了制备方法、新型中间体和药用盐。
• [EN] INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN<br/>[FR] COMPOSÉS D'INDOLE ET PROCÉDÉS DE TRAITEMENT DE LA DOULEUR VISCÉRALE
  申请人：NEURAXON INC

  公开号：WO2009062319A1

  公开（公告）日：2009-05-22

  The invention features methods of treating visceral pain or a condition in a mammal caused by the action of nitric oxide synthase (NOS) or by the action of serotonin 5HT1D/1B receptors, by administering to a patient in need thereof a therapeutically effective amount of an indole compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof. The methods of the invention may further comprise the administration of additional therapeutic agent. The invention also features new compounds of Formula (I), pharmaceutical compositions thereof, and methods of resolving enantiomeric mixtures.

  该发明涉及治疗哺乳动物体内因一氧化氮合酶（NOS）或5-羟色胺受体5HT1D/1B的作用引起的内脏疼痛或疾病的方法，通过向需要治疗的患者施用式(I)的吲哚化合物的治疗有效量，或其药学上可接受的盐或前药。该发明的方法还可以包括额外治疗剂的施用。该发明还涉及式(I)的新化合物、其药物组合物以及解决对映体混合物的方法。
• 3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY
  申请人：Annedi Subhash C.

  公开号：US20090131503A1

  公开（公告）日：2009-05-21

  The present invention relates to novel 3,5-substituted indole compounds of Formula (I) having nitric oxide synthase (NOS) inhibitory activity together with inhibitory activity at the norepinephrine transporter (NET), to pharmaceutical and diagnostic compositions containing them, and to their medical use.

  本发明涉及具有一氧化氮合酶（NOS）抑制活性以及对去甲肾上腺素转运蛋白（NET）具有抑制活性的新型3,5-取代吲哚化合物（I）的公式，以及含有它们的药用和诊断组合物，以及它们的医疗用途。
• Benzodioxane and benzodioxolane derivatives and uses thereof
  申请人：Zhou Dahui

  公开号：US20060241172A1

  公开（公告）日：2006-10-26

  Compounds of formula I or pharmaceutically acceptable salts thereof are provided: wherein each of R 1 , R 2 , R 3 , R 4 , y, n, m, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.

  提供了化学式I或其药用可接受盐的化合物：其中R1、R2、R3、R4、y、n、m和Ar中的每一个如所定义，并在此处描述的类和亚类中，它们是大脑5-羟色胺受体2C亚型的激动剂或部分激动剂。这些化合物和含有这些化合物的组合物可用于治疗多种中枢神经系统疾病，如精神分裂症。
• Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity
  申请人：Renton Paul

  公开号：US20080214613A1

  公开（公告）日：2008-09-04

  The present invention relates to benzimidazole compounds having dual nitric oxide synthase (NOS) inhibitory activity and agonist activity at the mu-opioid receptor, to pharmaceutical and diagnostic compositions containing them, and to their medical use, particularly as compounds for the treatment or prevention of chronic pain, acute pain, migraine, and neuropathic pain.

  本发明涉及具有双重一氧化氮合酶（NOS）抑制活性和μ-阿片受体激动活性的苯并咪唑化合物，以及包含它们的药物和诊断组合物，以及它们的医学用途，特别是作为治疗或预防慢性疼痛、急性疼痛、偏头痛和神经病性疼痛的化合物。